Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
Brilakis
Emmanouil S
ES
Banerjee
Subhash
S
D002140:California / Q000453:epidemiology; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000379:methods* / Q000401:mortality; D023903:Coronary Restenosis / Q000401:mortality / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D006083:Graft Occlusion, Vascular / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012501:Saphenous Vein / Q000637:transplantation*; D020123:Sirolimus / Q000008:administration & dosage*
D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus